SecBot SecBot
8-K ·Filed Apr 17, 2026

TOVX

Theriva Biologics, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed7mo ago SEC0001104659-26-044906
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

The positive Phase 2b data significantly de-risks the VCN-01 program and strengthens the company's position for partnerships, funding, or a potential acquisition. Traders should monitor for updates on the planned Phase 3 trial and any subsequent partnership announcements.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.4100
T+0 close · Apr 17, 2026 · via day close
Latest settled
−40.76%
T+60 · $0.2429
Vs SPY
−47.53%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 20 $0.4100entry
  2. T+1 · 7mo ago −17.07%α −16.42% · $0.3400
  3. T+5 · 7mo ago −14.63%α −15.55% · $0.3500
  4. T+20 · 6mo ago −26.83%α −31.03% · $0.3000
  5. T+60 · 4mo ago −40.76%α −47.53% · $0.2429
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Theriva Biologics announced positive results from its VIRAGE Phase 2b clinical trial, showing improved overall survival and progression-free survival in metastatic pancreatic cancer patients treated with VCN-01 plus chemotherapy. The data, to be presented at the AACR 2026 meeting, supports an immune-mediated mechanism of action and demonstrates consistent benefits across subgroups, including those with liver metastases.

Key Facts

  • Patients receiving VCN-01 + chemotherapy had improved overall survival (OS) and progression-free survival (PFS) compared to chemotherapy alone.
  • The survival benefit was maintained across subgroups, including patients with liver metastases.
  • Patients who received a second dose of VCN-01 showed a greater benefit in OS and PFS.
  • The company has achieved alignment with both the FDA and EMA on a proposed pivotal Phase 3 trial.
  • The data presentation is scheduled for the AACR Annual Meeting on April 20, 2026.

Financial Impact

No direct financial figures provided, but the positive clinical data significantly increases the potential value of the VCN-01 program.

drug development timelineregulatory pathwaymarket potential

Risk Factors

  • The data is from a Phase 2b trial and must be confirmed in a larger, pivotal Phase 3 study.
  • The company is small (market cap $12M) and may face challenges in funding and executing the Phase 3 trial without a partnership.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-044906
Document: tm2612012d1_ex99-1.htm0001104659-26-044906
Document: tm2612012d1_ex99-2.htm0001104659-26-044906
Document: 0001104659-26-044906-index-headers.html0001104659-26-044906
Document: 0001104659-26-044906-index.html0001104659-26-044906
Document: 0001104659-26-044906.txt0001104659-26-044906

Track record

11 reports on TOVX

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +17.39% at T+60 after the Aug 4, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.1600 to $0.1441 Now $0.1400 −12.50% ▼ −9.94% −9.57% vs SPY
  2. Nov 2, 202614d ago 8-K Neutral 5/10 Entry $0.1820 to $0.1900 Now $0.1400 −23.08% ▲ +4.40% +2.74% vs SPY
  3. Oct 20, 202627d ago DEF 14A Bearish 5/10 Entry $0.1966 to $0.1900 Now $0.1400 +28.79% ▲ +3.36% +2.18% vs SPY
  4. Aug 11, 202613w ago 8-K Neutral 4/10 No price data
  5. Aug 11, 202613w ago Press Release Neutral 5/10 Entry $0.2300 to $0.2400 Now $0.1400 −39.13% ▲ +4.35% +4.10% vs SPY
  6. Aug 4, 202614w ago 8-K Bearish 4/10 Entry $0.2300 to $0.2251 Now $0.1400 +39.13% ▲ +2.13% +1.93% vs SPY
  7. Jul 7, 202618w ago 8-K Bullish 5/10 Entry $0.2354 to $0.2378 Now $0.1400 −40.53% ▲ +1.02% +1.33% vs SPY
  8. Jun 11, 202622w ago Press Release Bullish 7/10 Entry $0.3070 to $0.3038 Now $0.1400 −54.40% ▼ −1.04% −1.58% vs SPY
  9. Apr 17, 202630w ago 8-K Bullish 7/10 Viewing Entry $0.4100 to $0.3400 Now $0.1400 −65.85% ▼ −17.07% −16.42% vs SPY
  10. Mar 12, 202635w ago 8-K Mixed 6/10 Entry $0.1800 to $0.1800 Now $0.1400 −22.22% · 0.00% +0.60% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 5h 53m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 17, 2026